PTNNasdaqPharmaceutical PreparationsFiscal year ends June 30
PALATIN TECHNOLOGIES INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 28, 2026
$5.99−0.03 (-0.50%)
Close on Oct 19, 2026
- Market cap
- $23.46M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
–
Operating margin
-98.2%−17799.5 pts over 5 years
Net margin
-94.9%−17908.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | +22.1% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -217.2% | -51.8% | -877.5% | |
| Return on assets | 73.0% | -44.1% | -142.1% | |
| Current ratio | 1.03 | 6.27 | 4.61 | |
| Debt to equity | -1.22 | – | – | |
| Net debt to EBITDA | -1.31× | – | – | |
| Interest coverage | 17.9× | -1424.2× | -1288.8× | |
| Inventory turnover | – | 0.3× | – | |
| Capex to revenue | 0.2% | -3.0% | 0.6% | |
| Diluted shares | 4M | 5M | 3M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Palatin Technologies generated $125.50M from operations and spent $789.13K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$125.50M
Used
$789.13K
Capital expenditure$789.13K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-94.9%
×Asset turnover1.50×
×Equity multiplier6.18×
=Return on equity, FY2026-877.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -94.9% | 1.50× | 6.18× | -877.5% |
| FY2024 | -662.3% | 0.31× | -13.71× | 2843.7% |
| FY2023 | -495.2% | 0.18× | 3.78× | -336.5% |
| FY2022 | -2465.1% | 0.03× | 1.57× | -109.8% |
| FY2021 | 17813.9% | -0.00× | 1.17× | -51.8% |
| FY2020 | -19006.9% | 0.00× | 1.05× | -24.8% |
| FY2019 | 59.3% | 0.84× | 1.13× | 56.1% |
| FY2018 | 36.8% | 1.40× | 4.40× | 226.6% |
| FY2017 | 36.8% | 1.98× | -2.98× | -217.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 7 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$8.38M
- Cash generatingOperating cash flow above zero-$13.53M
- Return on assets improvedROA up on the prior year-161.1% → -256.4%
- Earnings backed by cashOperating cash flow above net income-$13.53M vs -$8.38M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.36 → 4.61
- No dilutionShare count did not rise1M → 3M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 2.70